The second patient is a 75-year-old woman with left breast invasive carcinoma (ER+, PR weak, HER2-, PIK3CA gain of function mutation, PTEN truncating mutation, two TP53 missense mutations), status post neoadjuvant docetaxel and cyclophosphamide, left breast conservation therapy, radiation therapy, and aromatase inhibitor therapy. This evidence concerns the gene CYP19A1 and invasive breast carcinoma.